Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Eagle Health Investments LP

Eagle Health Investments LP increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 11.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 627,600 shares of the biopharmaceutical company's stock after acquiring an additional 65,900 shares during the quarter. Ultragenyx Pharmaceutical makes up approximately 6.5% of Eagle Health Investments LP's holdings, making the stock its 7th biggest holding. Eagle Health Investments LP owned approximately 0.68% of Ultragenyx Pharmaceutical worth $26,403,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Van ECK Associates Corp lifted its position in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 273 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after purchasing an additional 294 shares during the period. Motley Fool Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 0.3% in the 3rd quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company's stock valued at $8,005,000 after purchasing an additional 360 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 493 shares during the period. Finally, M&T Bank Corp increased its holdings in shares of Ultragenyx Pharmaceutical by 8.1% during the 3rd quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company's stock worth $388,000 after buying an additional 525 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RARE. Canaccord Genuity Group boosted their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. JPMorgan Chase & Co. increased their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Wedbush reissued a "neutral" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Finally, Wells Fargo & Company raised their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research note on Friday, December 20th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average target price of $92.79.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the sale, the executive vice president now directly owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Howard Horn sold 1,785 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the transaction, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 124,643 shares of company stock worth $5,256,268. Corporate insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 4.2 %

NASDAQ RARE traded down $1.58 during mid-day trading on Monday, reaching $36.25. 260,422 shares of the company's stock traded hands, compared to its average volume of 789,737. Ultragenyx Pharmaceutical Inc. has a 1-year low of $35.62 and a 1-year high of $60.37. The company has a fifty day simple moving average of $41.64 and a 200-day simple moving average of $46.77. The company has a market cap of $3.35 billion, a price-to-earnings ratio of -5.73 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.